A Prospective, Randomized Trial to Compare the Efficacy of OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) Invention versus Waitlisted Group in African American Adults with Hypertension (Preprint)

Author:

Still CarolynORCID,Harwell Carla,Killion CherylORCID,Sattar AbdusORCID,Viswanath SatishORCID

Abstract

BACKGROUND

For many adults living with hypertension, uncontrolled blood pressure (BP) leads to many adverse cardiovascular disease (CVD) events such as stroke, ischemic heart disease, chronic kidney failure, and other vascular diseases. Consistent adherence to prescribed hypertension treatment regimens is an important goal for persons living with hypertension, yet it remains a challenge for minority and underserved populations. Employing technology-based intervention (TBI) to support self-managing hypertension presents an opportunity to effectively control BP, and potentially have long-term effects on health outcomes.

OBJECTIVE

The objective of this study is to test the efficacy of a TBI, OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP), as an approach to support hypertension self-management to improve BP, health-related quality of life (HRQOL), and long-term compliance in African Americans with hypertension.

METHODS

This prospective, 2-arm randomized trial conducted in the Midwest will enroll African American older adults with hypertension, 50 years of age and older, recruited from primary clinics and community settings. Participants are allocated in a 1:1 ratio using computer-generated randomization to OPTIMA-BP intervention (n = 104) or Waitlist control group (n = 104). Participants are asked to participate in the study over a 12-month period and complete 5 study visits (baseline and follow-up at 3, 6, 9, and 12 months). Individuals in the OPTIMA-BP intervention group will receive three technology components (web-based education, medication adherence mHealth app, study provided home BP monitor), couple with nurse counselling and communication to providers for guideline-directed treatment regimen. We will also collect data on knowledge-attitude mechanisms of self-management (hypertension knowledge, self-efficacy, perceived social support) and proximal behavioral mechanisms (antihypertension medication-taking, diet, exercise). Qualitative analyses will explore participants' experiences with self-managing hypertension using technology.

RESULTS

Participant recruitment began in March 2022, and is currently ongoing. It is anticipated that preliminary findings appropriate for analysis will be disseminated Summer 2024. The primary endpoint is a change in systolic and diastolic BP (<130/80 mm Hg) and improved HRQOL.

CONCLUSIONS

Using TBI along with standard preventive measures provides a unique opportunity to improve BP control and enhance secondary CVD prevention in this high-risk group. By examining the mechanism by which the OPTIMA-BP intervention exerts its effect on self-managing hypertension, our study will advance both behavioral and self-management science.

CLINICALTRIAL

ClinicalTrials.gov NCT05564728; https://clinicaltrials.gov/study/NCT05564728

Publisher

JMIR Publications Inc.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3